Mvasi for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar – Details


( Last Updated : January 14, 2019)
Generic Name:
Bevacizumab
Project Status:
Complete
Therapeutic Area:
mCRC NSCLC Biosimilar
Manufacturer:
Amgen Canada Inc.
Brand Name:
Mvasi
Project Line:
Reimbursement Review
Project Number:
PC0158-000
NOC Status at Filing:
Post NOC
NOC Date:

Details

Strength:
100 mg and 400 mg
Tumour Type:
Gastrointestinal / Lung
Indications:
Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar
Funding Request:
For first-line treatment of patients with metastatic carcinoma of the colon or rectum, in combination with fluoropyrimidine based chemotherapy / For treatment of patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer, in combination with carboplatin/paclitaxel chemotherapy regimen
Sponsor:
Amgen Canada Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Recommendation Type:
N/A
Final Biosimilar Summary Dossier Issued:

Files

Provincial Funding Summary

Bevacizumab (Mvasi) mCRC NSCLC Biosimilar - Summary Dossier

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.